Trends in advanced breast cancer incidence rates after implementation of a mammography screening program in a German population

Cancer Epidemiology

Volumn 44, Issue , 2016, Pages 44-51

  Simbrich, Alexandra ^a   Wellmann, Ina ^a   Heidrich, Jan ^b   Heidinger, Oliver ^b   Hense, Hans Werner ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Epidemiological Cancer Registry for the State of North Rhine Westphalia   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GERMANY; GROUPS BY AGE; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; INCIDENCE; MIDDLE AGED; PATHOLOGY; PROCEDURES;

AGED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GERMANY; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED;

EID: 84979022136     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2016.07.006     Document Type: Article

References (33)

1. [1] Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg), Krebs in Deutschland 2009/2010, Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e V (Hrsg), 2013 (9. Ausgabe).
2. [2] Sant, M., Allemani, C., Capocaccia, R., et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int. J. Cancer 106:3 (2003), 416–422.
3. [3] Walters, S., Maringe, C., Butler, J., et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000–2007: a population-based study. Br. J. Cancer 108:5 (2013), 1195–1208.
4. [4] Giordano, L., von, K.L., Tomatis, M., et al. Mammographic screening programmes in Europe: organization, coverage and participation. J. Med. Screen. 19:Suppl. 1 (2012), 72–82.
5. [5] IARC Handbooks of Cancer Prevention, Volume 7: Breast Cancer Screening. 2002, IARC Press, Lyon, France.
6. [6] Foca, F., Mancini, S., Bucchi, L., et al. Decreasing incidence of late-stage breast cancer after the introduction of organized mammography screening in Italy. Cancer 119:11 (2013), 2022–2028.
7. [7] Fracheboud, J., Otto, S.J., van Dijck, J.A., Broeders, M.J., Verbeek, A.L., de Koning, H.J., Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br. J. Cancer 91:5 (2004), 861–867.
8. [8] Gangnon, R.E., Sprague, B.L., Stout, N.K., et al. The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model. Cancer Epidemiol. Biomarkers Prev. 24:6 (2015), 905–912.
9. [9] Helvie, M.A., Chang, J.T., Hendrick, R.E., Banerjee, M., Reduction in late-stage breast cancer incidence in the mammography era: implications for overdiagnosis of invasive cancer. Cancer 120:17 (2014), 2649–2656.
10. [10] Hofvind, S., Lee, C.I., Elmore, J.G., Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program. Breast Cancer Res. Treat. 135:1 (2012), 291–299.
11. [11] Autier, P., Boniol, M., Middleton, R., et al. Advanced breast cancer incidence following population-based mammographic screening. Ann. Oncol. 22:8 (2011), 1726–1735.
12. [12] Bleyer, A., Welch, H.G., Effect of three decades of screening mammography on breast-cancer incidence. N. Engl. J. Med. 367:21 (2012), 1998–2005.
13. [13] Lousdal, M.L., Kristiansen, I.S., Moller, B., Stovring, H., Trends in breast cancer stage distribution before, during and after introduction of a screening programme in Norway. Eur. J. Public Health 24:6 (2014), 1017–1022.
14. [14] Nederend, J., Duijm, L.E., Voogd, A.C., Groenewoud, J.H., Jansen, F.H., Louwman, M.W., Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study. Breast Cancer Res., 14(1), 2012, R10.
15. [15] Perry, N., Broeders, M., de Wolf, C., Tornberg, S., Holland, R., von Karsa, L., European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. fourth edition, 2006, Office for Official Publications of the European Communities, Luxembourg.
16. [16] van Buuren, S., Multiple imputation of discrete and continuous data by fully conditional specification. Stat. Methods Med. Res. 16:3 (2007), 219–242.
17. [17] Eisemann, N., Waldmann, A., Katalinic, A., Imputation of missing values of tumour stage in population-based cancer registration. BMC Med. Res. Methodol., 11, 2011, 129.
18. [18] European Commission, EUROSTAT: Methodologies and Working Papers.Revision of the European Standard Population, Report of Eurostat's task force (2013).
19. [19] Breslow, N.E., Day, N.E., The Design and Analysis of Cohort Studies. Statistical Methods in Cancer Research. Volume II. 1987, IARC Scientific Publications No.82, Lyon.
20. [20] Greenland, S., Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 6:4 (1995), 356–365.
21. [21] Stellungnahme des Wissenschaftlichen Gremiums des Beirates der Kooperationsgemeinschaft Mammographie, Verfahren zur Bewertung der Wirksamkeit des Deutschen Mammographie-Screening-Programms auf die Senkung der Sterblichkeit durch Brustkrebs, 2011, Stellungnahme des Wissenschaftlichen Gremiums des Beirats der Kooperationsgemeinschaft Mammographie vom 17.10.2011.
22. [22] Esserman, L., Shieh, Y., Thompson, I., Rethinking screening for breast cancer and prostate cancer. JAMA 302:15 (2009), 1685–1692.
23. [23] Autier, P., Boniol, M., Breast cancer screening: evidence of benefit depends on the method used. BMC Med., 10, 2012, 163.
24. [24] Day, N.E., Williams, D.R., Khaw, K.T., Breast cancer screening programmes: the development of a monitoring and evaluation system. Br. J. Cancer 59:6 (1989), 954–958.
25. [25] Tabar, L., Yen, A.M., Wu, W.Y., et al. Insights from the breast cancer screening trials: how screening affects the natural history of breast cancer and implications for evaluating service screening programs. Breast J. 21:1 (2015), 13–20.
26. [26] Lousdal, M.L., Kristiansen, I.S., Moller, B., Stovring, H., Effect of organised mammography screening on stage-specific incidence in Norway: population study. Br. J. Cancer 114:5 (2016), 590–596.
27. [27] Falk, R.S., Hofvind, S., Skaane, P., Haldorsen, T., Overdiagnosis among women attending a population-based mammography screening program. Int. J. Cancer 133:3 (2013), 705–712.
28. [28] Schott, G., Reichel, M., Junkermann, H., Becker, N., Retrospective quantification of background incidence and stage distribution of breast cancer for the mammography screening pilot project in Wiesbaden, Germany. J. Cancer Res. Clin. Oncol. 134:1 (2008), 29–35.
29. [29] www.tumorzentren.de/tl_files/dokumente/Qualitaetskonferenzen/5.%20Bundesweite%20Onkologische%20Qualitaetskonferenz%202014/Fachvortraege%20auf%20dem%20DKK%202014/DKK2014_Mamma_20140217_AGO.pdf (2016).
30. [30] Maaskant, A.J., van de Poll-Franse, L.V., Voogd, A.C., Coebergh, J.W., Tutein Nolthenius-Puylaert, M.C., Nieuwenhuijzen, G.A., Stage migration due to introduction of the sentinel node procedure: a population-based study. Breast Cancer Res. Treat. 113:1 (2009), 173–179.
31. [31] Tvedskov, T.F., Jensen, M.B., Balslev, E., Ejlertsen, B., Kroman, N., Stage migration after introduction of sentinel lymph node dissection in breast cancer treatment in Denmark: a nationwide study. Eur. J. Cancer 47:6 (2011), 872–878.
32. [32] Katalinic, A., Lemmer, A., Zawinell, A., Rawal, R., Waldmann, A., Trends in hormone therapy and breast cancer incidence—results from the German Network of Cancer Registries. Pathobiology 76:2 (2009), 90–97.
33. [33] Stang, A., Decline in hormone replacement prescription and fall in breast cancer incidence: an epidemiological discourse. Dtsch. Arztebl. Int. 105:16 (2008), 303–309.